Back to Agenda
Impact of Bayesian Methods in Drug Development with a Focus on Comparative Effectiveness Research
Session Chair(s)
Karen Lynn Price, PhD
Senior Research Fellow, Statistical Innovation Center/Design Hub
Eli Lilly and Company, United States
This forum will provide an overview of how Bayesian methods are used in practice, with particular emphasis on applications in comparative effectiveness research. We will focus on how such approaches can improve efficiency and provide clear quantitative development decisions.
This forum has been developed by the DIA Bayesian Scientific Working Group.
Learning Objective : Describe the efforts of the DIA Bayesian Scientific Working Group; Examine the value of the Bayesian approach across drug development, with a focus on comparative effectiveness research (CER); Discuss gaps in the use of Bayesian methods for CER including ways to meet gaps; Identify opportunities to collaborate in the future with the CER Scientific Working Group and Evidence-based Medicine Community, via open conversation across membership.
Speaker(s)
Bayesian Evidence Synthesis and Network Meta-Analysis in Context of CER
Bradley P. Carlin, PhD, MS
PharmaLex, United States
Senior Advisor, Data Science and Statistics
FDA Perspective
Ram Tiwari, PhD, MS
Bristol Myres Squibb , United States
Head of Statistical Methodology
Panelist
Matthew D. Rotelli, PhD, MS
Eli Lilly and Company, United States
Vice President, Bioethics
Have an account?